Travere Therapeutics, Inc.

Overview

1. "How the company got here" 2. "What it actually does" 3. "FILSPARI (sparsentan)" 4. "Thiola and Thiola EC (tiopronin)" 5. "Cholbam and Chenodal" 6. "What management is betting on now" 7. "Pipeline Programs" The company was founded in 2011 as Retrophin, Inc. and later rebranded as Travere Therapeutics in November 2020. Its early strategy involved acquiring rare disease assets and building a specialty pharmaceutical business. A significant turning point was the strategic refocus on rare kidney diseases, particularly IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), under new leadership. This shift led to the development and approval of FILSPARI, a key therapy that has become central to the company's current growth narrative. Travere's history also includes navigating governance challenges in its early years. Travere Therapeutics is a biopharmaceutical company that focuses on developing and delivering treatments for people with rare kidney and metabolic diseases. They identify diseases with significant unmet medical needs and work to create therapies that can make a meaningful difference in patients' lives. The company's approach involves both commercializing existing treatments and advancing a pipeline of new drug candidates through clinical development. Travere aims to provide life-changing therapies and support to patients and their families navigating rare conditions. FILSPARI is Travere's primary growth product and a cornerstone of its strategy in rare kidney diseases. It is an oral medication designed to slow the decline of kidney function in adults with primary IgA nephropathy (IgAN), a condition where the immune system mistakenly attacks the kidneys. FILSPARI is also approved for certain patients with focal segmental glomerulosclerosis (FSGS), another serious kidney disorder that can lead to kidney failure. The drug works by targeting two critical pathways involved in the progression of these kidney diseases. Thiola and Thiola EC are established medications used to treat cystinuria, a rare genetic disorder. Cystinuria causes high levels of a substance called cystine in the urine, which can lead to the frequent formation of kidney stones. These therapies, when used with increased fluid intake, alkali treatment, and dietary changes, help prevent the formation of cystine stones in patients with severe cases who haven't responded to other measures. Thiola and Thiola EC are part of Travere's legacy portfolio, which helps fund operations and development. Cholbam and Chenodal are part of Travere's legacy portfolio of rare disease treatments. Cholbam is a therapy used for rare bile-acid and liver-related disorders, helping Travere maintain relationships with specialist doctors who treat these conditions. Chenodal is another niche product within this older group of medications. While smaller in strategic importance compared to FILSPARI, these products remain relevant and contribute to the company's overall business. Travere's current strategy is centered on expanding the use of FILSPARI in IgA nephropathy (IgAN) and leveraging its success to launch the drug for focal segmental glomerulosclerosis (FSGS). The company aims to establish FILSPARI as a foundational treatment for these rare kidney conditions. Management is also focused on advancing its pipeline of investigational therapies and exploring opportunities to acquire or license new products in rare nephrology and metabolic diseases. This approach allows Travere to focus its resources on specific rare diseases where specialized commercial efforts and patient support can be most impactful. Travere is actively developing several pipeline programs targeting rare diseases. One key program is pegtibatinase (TVT-058), an investigational enzyme replacement therapy for classical homocystinuria (HCU), a genetic disorder affecting metabolism. The company is also exploring other potential therapies, such as civorebrutinib, an oral BTK inhibitor, which represents another future growth avenue. These pipeline efforts are crucial for Travere's long-term growth and its mission to address unmet medical needs in rare diseases.